ALK-Abelló

157.1

DKK

-2.6 %

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

15 following

-2.6%

-0.88%

-12.82%

+8.27%

+55.24%

+58.69%

-4.79%

+90.54%

+355.36%

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Market cap

35.01B DKK

Turnover

28.48M DKK

Revenue

4.82B

EBIT %

13.81 %

P/E

71.41

Dividend yield-%

-

Coverage

Financial calendar

19/2

2025

Annual report '24

13/3

2025

General meeting '24

6/5

2025

Interim report Q1'25

ShowingAll content types

Press release12/20/2024, 4:08 PM

ALK – Financial calendar for the 2025 financial year

Regulatory press release12/18/2024, 11:51 AM

Positive results advance peanut tablet to phase II development

Regulatory press release12/12/2024, 3:06 PM

ACARIZAX® approved in Europe for treatment of young children

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release11/27/2024, 12:45 PM

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

Regulatory press release11/14/2024, 6:30 AM

Nine-month interim report (Q3) 2024 (unaudited)

Regulatory press release11/9/2024, 10:29 PM

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Press release11/7/2024, 11:08 AM

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

Regulatory press release8/27/2024, 3:30 PM

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Regulatory press release8/22/2024, 3:49 PM

Six-month interim report (Q2) 2024

Regulatory press release8/22/2024, 3:38 PM

ALK upgrades its full-year revenue and earnings outlook

Press release8/14/2024, 9:58 AM

Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

Regulatory press release6/21/2024, 4:43 PM

ALK upgrades its full-year revenue and earnings outlook

Regulatory press release6/21/2024, 4:38 PM

ALK provides update on regulatory process for the house dust mite allergy tablet in China

Regulatory press release6/3/2024, 4:02 PM

ALK launches new growth strategy and 2028 financial ambitions

Press release6/3/2024, 5:00 AM

ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies

Press release5/30/2024, 11:44 AM

ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review

Press release5/29/2024, 8:56 AM

Listen in on ALK’s Capital Markets Day on 4 June 2024

Regulatory press release5/2/2024, 5:43 PM

Three-month interim report (Q1) 2024 (unaudited)

Regulatory press release5/2/2024, 5:26 PM

ALK upgrades its full-year revenue outlook

Press release4/24/2024, 2:35 PM

Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.